Premium
HLA‐G, HLA‐E, and IDO overexpression predicts a worse survival of Tunisian patients with vulvar squamous cell carcinoma
Author(s) -
Boujelbene Nadia,
Ben Yahia Hamza,
Babay Wafa,
Gadria Selma,
Zemni Ines,
Azaiez Houda,
Dhouioui Sabrine,
Zidi Nour,
Mchiri Rim,
Mrad Karima,
Ouzari HaddaImene,
Charfi Lamia,
Zidi Inès
Publication year - 2019
Publication title -
hla
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.347
H-Index - 99
eISSN - 2059-2310
pISSN - 2059-2302
DOI - 10.1111/tan.13536
Subject(s) - hla g , human leukocyte antigen , immunohistochemistry , vulvar carcinoma , immune system , medicine , oncology , carcinoma , immunology , antigen
Little is known about non‐classical HLA molecules in vulvar squamous cell carcinoma (VSCC). Because of the indoleamine‐2,3‐dioxygenase (IDO) immune tolerant role in association with HLA‐G, we evaluated the clinical and prognostic value of HLA‐G, HLA‐E, and IDO in VSCC. HLA‐G, HLA‐E, and IDO expression was determined by immunohistochemistry in VSCC and associated with clinicopathological parameters and disease outcome. These three molecules were highly represented in tumoral tissues vs healthy matched vulvar tissues ( P = 0.0001). Significant differences in HLA‐G expression in stages, tumor size, tumor invasion depth, and resection margins subgroups were reported ( P < 0.05). At 5 years, the cumulative survival rates was of 79.8% in patients with HLA‐G low expression vs 12.5% in those with HLA‐G high expression ( P < 3 × 10 −5 ). Similarly, patients with IDO high expression were at a significantly reduced overall survival (OS) and disease‐free survival (DFS) rates ( P = 0.011 and 0.045, respectively). The overexpression of the three molecules together worsen survival rates of VSCC patients (OS: P = 0.000038, DFS: P = 0.000085). Altogether, our results showed that HLA‐G, HLA‐E, and IDO may represent novel candidate markers for patients' prognosis and potential targets for VSCC therapy.